Enzyme‐Instructed Intracellular Molecular Self‐Assembly to Boost Activity of Cisplatin against Drug‐Resistant Ovarian Cancer Cells |
| |
Authors: | Jie Li Yi Kuang Junfeng Shi Jie Zhou Jamie E. Medina Rong Zhou Dan Yuan Cuihong Yang Huaimin Wang Prof. Zhimou Yang Prof. Jianfeng Liu Prof. Dr. Daniela M. Dinulescu Prof. Dr. Bing Xu |
| |
Affiliation: | 1. Department of Chemistry, Brandeis University, 415 South St, Waltham, MA 02454 (USA);2. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 (USA);3. Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192 (P.R. China);4. State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin 300071 (China) |
| |
Abstract: | Anticancer drug resistance demands innovative approaches that boost the activity of drugs against drug‐resistant cancers without increasing the systemic toxicity. Here we show the use of enzyme‐instructed self‐assembly (EISA) to generate intracellular supramolecular assemblies that drastically boost the activity of cisplatin against drug‐resistant ovarian cancer cells. We design and synthesize small peptide precursors as the substrates of carboxylesterase (CES). CES cleaves the ester bond pre‐installed on the precursors to form the peptides that self‐assemble in water to form nanofibers. At the optimal concentrations, the precursors themselves are innocuous to cells, but they double or triple the activity of cisplatin against the drug‐resistant ovarian cancer cells. This work illustrates a simple, yet fundamental, new way to introduce non‐cytotoxic components into combination therapies with cisplatin without increasing the systemic burden or side effects. |
| |
Keywords: | cisplatin combination therapy drug‐resistance enzymes self‐assembly |
|
|